Literature DB >> 23392737

Semiparametric inference on the absolute risk reduction and the restricted mean survival difference.

Song Yang1.   

Abstract

For time-to-event data, when the hazards are non-proportional, in addition to the hazard ratio, the absolute risk reduction and the restricted mean survival difference can be used to describe the time-dependent treatment effect. The absolute risk reduction measures the direct impact of the treatment on event rate or survival, and the restricted mean survival difference provides a way to evaluate the cumulative treatment effect. However, in the literature, available methods are limited for flexibly estimating these measures and making inference on them. In this article, point estimates, pointwise confidence intervals and simultaneous confidence bands of the absolute risk reduction and the restricted mean survival difference are established under a semiparametric model that can be used in a sufficiently wide range of applications. These methods are motivated by and illustrated for data from the Women's Health Initiative estrogen plus progestin clinical trial.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392737     DOI: 10.1007/s10985-013-9243-y

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  7 in total

1.  Causal inference on the difference of the restricted mean lifetime between two groups.

Authors:  P Y Chen; A A Tsiatis
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Estimation of the 2-sample hazard ratio function using a semiparametric model.

Authors:  Song Yang; Ross L Prentice
Journal:  Biostatistics       Date:  2010-09-21       Impact factor: 5.899

3.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Stat Med       Date:  2011-05-25       Impact factor: 2.373

4.  Double inverse-weighted estimation of cumulative treatment effects under nonproportional hazards and dependent censoring.

Authors:  Douglas E Schaubel; Guanghui Wei
Journal:  Biometrics       Date:  2011-03       Impact factor: 2.571

5.  Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.

Authors:  Ross L Prentice; Robert Langer; Marcia L Stefanick; Barbara V Howard; Mary Pettinger; Garnet Anderson; David Barad; J David Curb; Jane Kotchen; Lewis Kuller; Marian Limacher; Jean Wactawski-Wende
Journal:  Am J Epidemiol       Date:  2005-07-20       Impact factor: 4.897

6.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

7.  Estrogen plus progestin and the risk of coronary heart disease.

Authors:  JoAnn E Manson; Judith Hsia; Karen C Johnson; Jacques E Rossouw; Annlouise R Assaf; Norman L Lasser; Maurizio Trevisan; Henry R Black; Susan R Heckbert; Robert Detrano; Ora L Strickland; Nathan D Wong; John R Crouse; Evan Stein; Mary Cushman
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

  7 in total
  4 in total

1.  Semiparametric simultaneous confidence bands for the difference of survival functions.

Authors:  Nubyra Ahmed; Sundarraman Subramanian
Journal:  Lifetime Data Anal       Date:  2015-10-14       Impact factor: 1.588

2.  Six articles related to risk assessment and prediction based on work presented at the October 12–14, 2011 Conference on Risk Assessment and Evaluation of Predictions in Silver Spring, Maryland.

Authors:  Mitchell H Gail; Ruth M Pfeiffer; Tianxi Cai
Journal:  Lifetime Data Anal       Date:  2013-04       Impact factor: 1.588

3.  Assessing potentially time-dependent treatment effect from clinical trials and observational studies for survival data, with applications to the Women's Health Initiative combined hormone therapy trial.

Authors:  Song Yang; Ross L Prentice
Journal:  Stat Med       Date:  2015-02-17       Impact factor: 2.373

4.  A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves.

Authors:  Hajime Uno; Lu Tian; Brian Claggett; L J Wei
Journal:  Stat Med       Date:  2015-07-20       Impact factor: 2.373

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.